Anti-inflammatory effects of medications used for viral infection-induced respiratory diseases

Yamaya, Mutsuo; Kikuchi, Akiko; Sugawara, Mitsuru; Nishimura, Hidekazu

doi:10.1016/j.resinv.2022.11.002

Cited by 10 publications

(7 citation statements)

References 153 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, the use of macrolides has been based more on their potential anti-inflammatory and immunoregulatory effects, which have been demonstrated in both in vitro experimental models and other inflammatory lung diseases. As immunomodulators, they play a role in regulating cytokines such as interleukin (IL)-Iβ, IL-6, IL-10, and TNF-α [43]. Particularly, erythromycin and clarithromycin have been shown to suppress the production of IL-8 and IL-33 during RS virus infection [43].…”

Section: Discussionmentioning

confidence: 99%

“…As immunomodulators, they play a role in regulating cytokines such as interleukin (IL)-Iβ, IL-6, IL-10, and TNF-α [43]. Particularly, erythromycin and clarithromycin have been shown to suppress the production of IL-8 and IL-33 during RS virus infection [43]. Azithromycin inhibits the production of proinflammatory cytokines, reduces neutrophil infiltration, and promotes macrophage accumulation [44].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Effectiveness and Safety of Long-Term Macrolide Therapy for COPD in Stable Status: A Systematic Review and Meta-Analysis

Nakamura,

Fujita,

Chen

et al. 2023

Diseases

View full text Add to dashboard Cite

Background: Chronic obstructive pulmonary disease (COPD) is a prevalent condition with fewer treatments available as the severity increases. Previous systematic reviews have demonstrated the benefits of long-term macrolide use. However, the therapeutic differences between different macrolides and the optimal duration of use remain unclear. Methods: A systematic review and meta-analysis were conducted to assess the effectiveness of long-term macrolide use in reducing COPD exacerbations, compare the therapeutic differences among macrolides, and determine the appropriate treatment duration. Four databases (PubMed, Cochrane Library, Web of Science, and ICHU-SHI) were searched until 20 March 2023, and a random-effects model was used to calculate the pooled effect. Results: The meta-analysis included nine randomized controlled trials involving 1965 patients. The analysis revealed an odds ratio (OR) of 0.34 (95% confidence interval [CI] 0.19, 0.59, p < 0.001) for the reduction in exacerbation frequency. Notably, only azithromycin or erythromycin showed suppression of COPD exacerbations. The ORs for reducing exacerbation frequency per year and preventing hospitalizations were −0.50 (95% CI: −0.81, −0.19; p = 0.001) and 0.60 (95% CI: 0.3, 0.97; p = 0.04), respectively. Statistical analyses showed no significant differences between three- and six-month macrolide prescriptions. However, studies involving a twelve-month prescription showed an OR of 0.27 (95% CI: 0.11, 0.68; p = 0.005; I2 = 81%). Although a significant improvement in St George’s Respiratory Questionnaire (SGRQ) total scores was observed with a mean difference of −4.42 (95% CI: −9.0, 0.16; p = 0.06; I2 = 94%), the minimal clinically important difference was not reached. While no adverse effects were observed between the two groups, several studies have reported an increase in bacterial resistance. Conclusions: Long-term use of azithromycin or erythromycin suppresses COPD exacerbations, and previous studies have supported the advantages of a 12-month macrolide prescription over a placebo.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The Effectiveness and Safety of Long-Term Macrolide Therapy for COPD in Stable Status: A Systematic Review and Meta-Analysis

Nakamura,

Fujita,

Chen

et al. 2023

Diseases

View full text Add to dashboard Cite

show abstract

“…To our knowledge, no cases have been reported in COVID‐19 paediatric patients. The mechanism may be related to the persistent and severe ‘cytokine storm’ caused by COVID‐19, which causes excessive fibrin deposition in the lung, 4 and enhances antigen‐induced airway inflammation and hyperresponsiveness 5 …”

Section: Answermentioning

confidence: 99%

Bronchial tree‐shaped mucus plugs caused by COVID‐19

Yang,

Chi

2024

J Paediatrics Child Health

View full text Add to dashboard Cite

“…CSF3R is associated with may indirectly affect the course, severity, and duration of in uenza infection [71,72].…”

Section: Dr Is An Important Major Histocompatibility Complex (Mhc) Cl...mentioning

confidence: 99%

Combination of multidisciplinary approaches reveals potential causal associations between influenza and immune cells: Single-cell RNA sequencing and Mendelian randomization

Guo,

Wu,

Chen

et al. 2024

Preprint

View full text Add to dashboard Cite

Background The relationship between immune cells and influenza is a battle between the host immune system and viral invaders, however, the causality and underlying mechanisms have not been fully elucidated. Methods This study first analysed disability-adjusted life years (DALYs) and mortality of influenza using descriptive epidemiology based on the Global Burden of Disease (GBD) data from 1990 to 2019. Potential causal associations between 731 immune cells and influenza were then explored using univariate Mendelian randomization (UVMR), followed by validation of the cellular subpopulations to which the immune cells identified by UVMR belonged at the single-cell level, and then enrichment analysis has been performed. Finally, we also performed MR of key genes in cellular subpopulations, reverse MR analysis, colocalization analysis, potential drug prediction and molecular docking for genes satisfying causal associations. Results Joinpoint regression trend analysis showed a general downward trend in the change of influenza DALYs rate and mortality rate, and then UVMR results showed a strong association between the immune cell HLA-DR on CD14+ CD16- monocyte and influenza (PIVW = 5.47E-05, PFDR = 0.03). The single-cell sequencing (scRNA-Seq) results verified that the immune cell HLA-DR on CD14+ CD16- monocyte identified by UVMR belonged to the Classical monocytes (CMs) subpopulation. MR analysis of key genes in the cellular subpopulation identified a total of 7 genes as causally associated with influenza, and no reverse causal association was found. The 3 genes were identified as druggable by drug prediction, namely VIM, CTSA and CSF3R. Finally, molecular docking results demonstrated the strong potential of the CSF3R gene as a drug target. Conclusions Our study provides new insights into future prevention and treatment strategies for influenza from epidemiology to genetics to bioinformatic analyses and genomic.

show abstract

Anti-inflammatory effects of medications used for viral infection-induced respiratory diseases

Cited by 10 publications

References 153 publications

The Effectiveness and Safety of Long-Term Macrolide Therapy for COPD in Stable Status: A Systematic Review and Meta-Analysis

The Effectiveness and Safety of Long-Term Macrolide Therapy for COPD in Stable Status: A Systematic Review and Meta-Analysis

Bronchial tree‐shaped mucus plugs caused by COVID‐19

Combination of multidisciplinary approaches reveals potential causal associations between influenza and immune cells: Single-cell RNA sequencing and Mendelian randomization

Contact Info

Product

Resources

About